Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323310 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of MultiHance in Pediatric Patients
A Phase 3 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
NCT00323310 is a Phase 3 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 92 participants.
The verdict
NCT00323310, a Phase 3 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety and enhancing properties of the magnetic resonance imaging (MRI) contrast agent MultiHance in children aged 2 to 17 years having central nervous system (CNS) disorders.
Interventions
- DRUG gadobenate dimeglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323310
The ClinicalTrials.gov registry entry for NCT00323310 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gadobenate dimeglumine is the first listed.
NCT00323310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00323310 about?
NCT00323310 is a clinical study titled "Safety and Efficacy of MultiHance in Pediatric Patients". The purpose of this study was to assess the safety and enhancing properties of the magnetic resonance imaging (MRI) contrast agent MultiHance in children aged 2 to 17 years having central nervous system (CNS) disorders.
What is the current status of trial NCT00323310?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2006-04. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00323310?
The interventions under investigation include: gadobenate dimeglumine (DRUG).
Who is sponsoring clinical trial NCT00323310?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.